Modality
Radioligand
MOA
HER2
Target
ALK
Pathway
JAK/STAT
RACKD
Development Pipeline
Preclinical
~Oct 2018
→ ~Jan 2020
Phase 1
Apr 2020
→ Aug 2027
Phase 1Current
NCT05472272
23 pts·RA
2020-04→2027-08·Active
23 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-08-261.4y awayInterim· RA
Trial Timeline
Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P1
Active
Catalysts
Interim
2027-08-26 · 1.4y away
RA
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05472272 | Phase 1 | RA | Active | 23 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| MRK-8368 | Merck & Co | Phase 3 | ALK | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| GSK-6983 | GSK | Phase 2 | ALK | |
| TAK-9344 | Takeda | Phase 3 | CGRP | |
| BAY-3308 | Bayer | Phase 1 | ALK | |
| Tixarelsin | Vertex Pharma | Phase 1 | ALK | |
| VRT-6833 | Vertex Pharma | Preclinical | ALK |